CELLINK will acquire all outstanding shares of Nanoscribe in a two-phase cash and stock agreement. The initial purchase price will be £34 million ($48.01 million) followed by a €16 million ($22.6 million) payment in earn-outs.
The two-photon polymerization additive manufacturing technology enables bioprinting of vascular microenvironments at the subcellular scale, suitable for cell studies and lab-on-a-chip applications, which is expected to contribute to CELLINK’s product development. The addition, the company said in a press release, will deliver additional revenue through the fabrication of implants, microneedles, microporous membranes, and consumables for omics applications.
“The life science industry is currently going through a very exciting transformation where many processes and technologies are being miniaturized to increase throughput and reduce cost, where price of reagents is a major bottleneck for sequencing,” both companies said in the shared portion of separate releases. “One example is the sample preparation steps for single-cell genomics applications. With Nanoscribe’s microfabrication technologies, the CELLINK Group stays competitive in this transformation and aims to miniaturize devices for a wide range of applications, resulting in internal capabilities to further expand its consumables offering across all business areas.”
Nanoscribe is expected to generate €15.4 million ($21.74 million) in revenue in 2021.
CELLINK followed up its purchase of Nanoscribe with its acquisition of Visikol for $7.5 million. The group anticipates the ability to offer additional elements in the drug discovery process by combining the Visikol HISTO tissue clearing reagents with cloud-based technology for analysis, advanced imaging with digital pathology, and 3D cell culture assays. The acquisition provides CELLINK with a new market segment in the contract research market, CELLINK stated in a press release. Visikol will be part of the group’s bioprinting business area. It is expected to generate $3 million of revenue in 2021.
